TT levels reported were low.
I can’t see any advantge VS Nolvadex. But the new drug will be way more expensive.
The side effects from Comid that some guys report, cannot be blocked by an AI, the SERM is the ‘estrogen’.
All SERM’s increase estrogens. That is a simple result of what is happening in the testes.
An AI should be used with a SERM if E2 becomes elevated. However, if the SERM dose is too much for the testes, there can be a lot of T–>E2 inside the testes and a competative AI cannot control that T–>E2
Comparing to transdermal T products is a silly soft target.
Some of the trandermal T reports of non-success probably include those who simply cannot absorb or have that problem because of hypothyroidism. In those cases, transdermals are simply inapropriate. Again cherry picking. Should compare to the gold standard - injections.
SERM’s will not help with some forms of seconary hypogonadism and never with primary. And old testes often willl not produce decent levels of T with LH/FSH from a SERM or with hCG. SERM’s can work well with younger men. That is a rather small market.
Based on the TT levels reported, I would judge this treatment as a total failure. We have young and old guys at the achived levels who feel like crap. Older men need to be high-normal to feel good.
Few corrections to your post:
- The phase 3 trial was considered a “massive” success as 89% of subjects doubled their tt levels.
- Clomiphene is $1.12 per 50mg tablet. If androxal is sold at $100 per 50mg tablet…it will still be cheaper then test cyp for a 1 month supply.
- If tamoxifen worked better then enclomiphene, then $50 million dollars worth of research would be going into that drug and not this one.
- Enclomiphene does not promote estrogenic activity…it simply occupies the receptor site…similar to how suboxone occupies opiate receptors but doesn’t get you high.
- Serms help with all forms of secondary as by definition, secondary hypogonadism is a failure in the chemical signaling between the 3 parts of the gonadal axis. If the serm doesn’t work for someone who was diagnosed as secondary…them they were diagnosed wrong and they are really primary.
Your comment that the study was a total failure is your subjective opinion. Thankfully the FDA doesn’t share your lack of objectivity. Normally I would supply clinical literature to support what I say but I’m not getting into a pissing contest with an undercover androgel cyber salesman.